Bleeding pattern, tolerance and patient satisfaction with a drospirenone-containing oral contraceptive evaluated in 3488 women in Europe, the Middle East and Canada

Endrikat, Jan; Milchev, N; Kapamadzija, Aleksandra; Georgievska, Jadranka; Gerlinger, Christoph; Schmidt, W.; Feroze, S

doi:10.1016/j.contraception.2008.12.007

Cited by 13 publications

(10 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our results of this sub-analysis confirm the trends seen in the overall evaluation reported in 2009 [9]: DRSP/EE drastically reduces intermenstrual bleeding, dysmenorrea (Figure 1), heavy bleedings (Figure 2) and signs of water retention like abdominal bloating and breast tenderness (Figure 3). In contrast, amenorrhea and incidence of swelling extremities remained relatively stable in Jordan which might be explainable be the high percentage of OC users at baseline (49.8% in Jordan vs. 35.9% in Lebanon and 38.6% in Syria).…”

Section: Discussionsupporting

confidence: 78%

“…A total of 914 women were included from 3 countries in the Middle East as part of a sub-analysis that comprised 3,488 women in Europe, the Middle East and Canada [9]. The target parameters were bleeding pattern, clinical signs of water retention and patient satisfaction.…”

Section: Discussionmentioning

confidence: 99%

“…The whole data set comprising 3488 women in Europe, the Middle East and Canada was published in 2009 [9].…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

A drospirenone-containing oral contraceptive improved bleeding pattern and personal satisfaction in 914 women from Jordan, Lebanon and Syria

Finan¹,

Annab²,

Abdalla³

et al. 2013

Health

Self Cite

View full text Add to dashboard Cite

Section: Discussionsupporting

confidence: 78%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

A drospirenone-containing oral contraceptive improved bleeding pattern and personal satisfaction in 914 women from Jordan, Lebanon and Syria

Finan¹,

Annab²,

Abdalla³

et al. 2013

Health

Self Cite

View full text Add to dashboard Cite

“…In one study, unscheduled bleeding after cycle 6 was reported at 8.8%32, and in another study, an incidence of 5.4% was reported34. A possible explanation for the observed higher incidence of unscheduled bleeding/spotting is the use of the more accurate electronic diaries in the current study instead of paper diary cards or a woman's personal recollection during clinic visits32,34,35. In the current study, women could only enter the daily bleeding information retrospectively for the previous two days, providing very accurate values for the incidence of unscheduled bleeding/spotting, likely resulting in the higher incidences for DRSP/EE users than observed with paper diaries.…”

Section: Discussionmentioning

confidence: 93%

Efficacy and tolerability of a monophasic combined oral contraceptive containing nomegestrol acetate and 17β-oestradiol in a 24/4 regimen, in comparison to an oral contraceptive containing ethinylestradiol and drospirenone in a 21/7 regimen

Mansour¹,

Verhoeven

Sommer

et al. 2011

The European Journal of Contraception & Reproductive Health

View full text Add to dashboard Cite

ObjectivesThe primary objective was to assess the efficacy, cycle control and tolerability of a monophasic combined oral contraceptive (COC) containing nomegestrol acetate (NOMAC) and 17β-oestradiol (E2). Effects on acne were evaluated as a secondary objective. Results were compared to those of a COC containing drospirenone (DRSP) and ethinylestradiol (EE).MethodsWomen (aged 18-50 years) were randomised to receive NOMAC/E2 (2.5 mg/1.5 mg) in a 24/4-day regimen (n = 1591) or DRSP/EE (3 mg/30 μg) in a 21/7-day regimen (n = 535) for 13 cycles.ResultsEstimated Pearl Indices for NOMAC/E2 and DRSP/EE were 0.38 and 0.81 in women aged ≤ 35 years and 0.31 and 0.66 for all women (18–50 years), respectively. Scheduled withdrawal bleedings were shorter and lighter among users of NOMAC/E2 and were sometimes absent altogether. Intracyclic bleeding/spotting was infrequent in both groups, and decreased over time. Type and frequency of adverse events were similar to those typically reported for COCs.ConclusionsThese data show that NOMAC/E2 provides high contraceptive efficacy with acceptable cycle control as well as an overall adverse event profile similar to that of DRSP/EE.

show abstract

“…Among the five OC products presented and described to survey participants, the most favoured formulation irrespective of behavioural segment was 3 mg drospirenone + 0.03 mg ethinylestradiol (31–39% selection rate across segments). Described as having a proven low influence on body weight and providing adequate cycle control with low incidence of intermenstrual bleeding, amenorrhoea and dysmenorrhoea [ 29 – 34 ], it is likely that these attributes have broad appeal. The second-place positioning of 0.075 mg gestodene + 0.02 mg ethinylestradiol (28%) in the Low Hormone Content group and of 2 mg chlormadinone + 0.03 mg ethinylestradiol (26%) in the Beauty group, was consistent with each segment.…”

Section: Discussionmentioning

confidence: 99%

Needs and preferences of women users of oral contraceptives in selected countries in Central and Eastern Europe

Fait¹,

Buryak²,

Cirstoiu³

et al. 2018

DIC

View full text Add to dashboard Cite

BackgroundThe availability of various oral contraceptive (OC) pill formulations with different hormone compositions suggests that there is potential to align a particular product with an individual user’s needs and preferences. To explore this concept further, a survey was conducted of current users of OCs to define and confirm areas of specific needs, and to gain insight into their views and preferences for OC formulations.MethodsDuring November and December 2015, women users (n=615) of OCs in five Central and Eastern European countries were surveyed in face-to-face interviews conducted by experienced interviewers. The survey questionnaire comprised 34 questions about the use of and specific needs for OCs.ResultsFour basic needs of women taking OCs were identified: reliable contraception, reversibility of contraception, no effect on body weight and safety. Overall, 85% of surveyed women indicated that prevention of pregnancy was the main reason for taking OCs. Weight gain was the side effect of greatest concern with OC use (46% spontaneous answer; 65% aided answer). Independent behavioural segmentation analysis identified four groups – Solved Cycle Problems (46% of participants), Low Hormone Content (22%), Lifestyle (17%) and Beauty (14%) – which characterised the women according to needs and preferences beyond the basic needs of OCs. Each group had unique features and distinct preferences for different formulations of OCs.ConclusionsAligning product advantages with specific individual needs may enhance users’ overall experience with OCs as a contraceptive option.

show abstract

Bleeding pattern, tolerance and patient satisfaction with a drospirenone-containing oral contraceptive evaluated in 3488 women in Europe, the Middle East and Canada

Cited by 13 publications

References 18 publications

A drospirenone-containing oral contraceptive improved bleeding pattern and personal satisfaction in 914 women from Jordan, Lebanon and Syria

A drospirenone-containing oral contraceptive improved bleeding pattern and personal satisfaction in 914 women from Jordan, Lebanon and Syria

Efficacy and tolerability of a monophasic combined oral contraceptive containing nomegestrol acetate and 17β-oestradiol in a 24/4 regimen, in comparison to an oral contraceptive containing ethinylestradiol and drospirenone in a 21/7 regimen

Needs and preferences of women users of oral contraceptives in selected countries in Central and Eastern Europe

Contact Info

Product

Resources

About